Market Scorecard
Market Pathways Scorecard: Q1 FDA Authorizations
A graphical look at FDA novel device approvals, 510(k)s, and PMA supplements during the first quarter of 2026.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Start-Ups
SleepRes: A Breathtaking New Apnea Therapy
Greater comfort plus rivaling effectiveness equals better therapeutic adherence, according to this start-up’s philosophy.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Regulatory & Reimbursement
Pathways' Pick of the Week: Billion-Dollar Budget
User fees would bankroll more than half of the FDA’s FY2027 budget request. Excerpted from Pathways’ Picks April 7: Shuren Venture Fund, MDUFA Agreement, Global Digital Health Updates.